News and features

The Institute of Cancer Research, London, and science and technology company Merck have renewed their strategic alliance in the discovery and development of new cancer drugs.

Apollo Therapeutics, a strategic partner of The Institute of Cancer Research, has raised more than $226m from investors to fund its ongoing collaboration with the ICR and other academic partners.

Researchers have developed an investigative procedure that makes the early stages of drug discovery more efficient.

A new radioactive medicine that seeks out tumour cells to deliver a targeted dose of radiation greatly improves quality of life for patients with advanced prostate cancer, a phase III study finds.

Researchers have found a way to use a simple, non-invasive scan to tell whether an experimental approach to enhance treatment for breast cancer is effective.

A new study has provided insights into an important biological mechanism that supports survival of aggressive, hard-to-treat cancers – and in the process, uncovered fascinating new information about how cells divide and grow.

A new form of screening may improve survival rates among people with a fast-growing type of brain tumour by helping identify those most likely to benefit from certain treatments.

A new study sheds light on the genetic messages encoded by genes within ‘triple negative’ breast cancers – and poses important questions on how they could be better treated in future.

Existing targeted cancer drugs could help even more patients, including some with the most common type of breast cancer, scientists have discovered.

Scientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers.

Olympic gold medallist Greg Rutherford MBE and Paralympic gold medallist Erin Kennedy MBE launch an inspirational run for the ICR across 100 miles of British coastline – which will see ‘FINISH CANCER’ imprinted 167,000 times in the sand.

Professor Nicholas Turner, Professor of Molecular Oncology at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, where he is also Head of the Ralph Lauren Centre for Breast Cancer Research, has received the Translational Research Award by the European Society for Medical Oncology (ESMO).